Protection Induced by Simultaneous Subcutaneous and Endobronchial Vaccination with BCG/BCG and BCG/Adenovirus Expressing Antigen 85A against Mycobacterium bovis in Cattle

Dean, Gillian S.; Clifford, Derek; Whelan, Adam O.; Tchilian, Elma; Beverley, Peter C. L.; Salguero, Francisco J.; Xing, Zhou; Vordermeier, H. M.; Villarreal‐Ramos, Bernardo

doi:10.1371/journal.pone.0142270

Cited by 32 publications

(30 citation statements)

References 21 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in cattle, the simultaneous administration of BCG endobronchially and systemically, resulted in significant protection against M.bovis infection compared to unvaccinated control animals [84].…”

Section: Bcg and Attenuated Whole-cell Live Vaccinesmentioning

confidence: 96%

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

Stylianou

Paul

Reljić

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could be achieved. The route of entry of Mycobacterium tuberculosis, the causative organism, is via inhalation making TB primarily a respiratory disease. There is therefore good reason to hypothesize that a mucosally delivered vaccine against TB could be more effective than one delivered via the systemic route. Areas covered: This review summarizes the progress that has been made in the area of TB mucosal vaccines in the last few years. It highlights some of the strengths and shortcomings of the published evidence and aims to discuss immunological and practical considerations in the development of mucosal vaccines. Expert opinion: There is a growing body of evidence that the mucosal approach to vaccination against TB is feasible and should be pursued. However, further key studies are necessary to both improve our understanding of the protective immune mechanisms operating in the mucosa and the technical aspects of aerosolized delivery, before such a vaccine could become a feasible, deployable strategy.

show abstract

Section: Bcg and Attenuated Whole-cell Live Vaccinesmentioning

confidence: 96%

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

Stylianou

Paul

Reljić

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“… 43 Alongside murine protections studies, guinea pig, bovine, and a recently published nonhuman primate studies have shown significantly greater bacterial control and survival of animals immunized via the respiratory mucosal route with AdHu5Ag85A. 41 , 46 , 47 , 49 The potential of AdHu5Ag85A has been further supported by a recently completed phase-1 clinical trial where intramuscular administration of AdHu5Ag85A induced polyfunctional CD4 + and CD8 + T-cell responses particularly in Bacillus Calmette Guerin+ human volunteers. 50 A second clinical trial assessing the safety and immunogenicity of AdHu5Ag85A delivered by inhaled aerosol is to be launched soon in Canada.…”

Section: Preclinical and Clinical Development Of Adenovirus-based Vacmentioning

confidence: 98%

Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens

Afkhami

Yao

Xing

2016

Molecular Therapy - Methods & Clinical Development

Self Cite

View full text Add to dashboard Cite

Adenoviruses represent the most widely used viral-vectored platform for vaccine design, showing a great potential in the fight against intracellular infectious diseases to which either there is a lack of effective vaccines or the traditional vaccination strategy is suboptimal. The extensive understanding of the molecular biology of adenoviruses has made the new technologies and reagents available to efficient generation of adenoviral-vectored vaccines for both preclinical and clinical evaluation. The novel adenoviral vectors including nonhuman adenoviral vectors have emerged to be the further improved vectors for vaccine design. In this review, we discuss the latest adenoviral technologies and their utilization in vaccine development. We particularly focus on the application of adenoviral-vectored vaccines in mucosal immunization strategies against mucosal pathogens including Mycobacterium tuberculosis, flu virus, and human immunodeficiency virus.

show abstract

“…Details of the vaccination and infection protocols for studies 1 (3), 2 (20), and 3 (21) are as previously described. For study 4, male Holstein Friesian calves were vaccinated with BCG Danish SSI subcutaneously (s.c.) (equivalent to 5 human doses) at approximately 6 weeks of age.…”

Section: Animals (I) Bcg-vaccinated M Bovis-infected Animalsmentioning

confidence: 99%

Tuberculin Skin Testing Boosts Interferon Gamma Responses to DIVA Reagents in Mycobacterium bovis-Infected Cattle

Jones

Coad

Khatri

et al. 2017

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

Mycobacterium bovis BCG vaccination sensitizes cattle to bovine tuberculin, which compromises the use of the current bovine tuberculosis (TB) surveillance tests. Although the performance of a blood test (that utilizes antigens expressed by Mycobacterium bovis but not by BCG) capable of discriminating infected from vaccinated animals (DIVA interferon gamma test [DIT]) has been evaluated in naturally infected TB field reactors, there is a need to perform similar analysis in a BCG-vaccinated M. bovis-infected population. Furthermore, we explored different scenarios under which a DIT may be implemented alongside BCG vaccination: (i) serial testing to resolve potential false-positive skin test results or (ii) a standalone test to replace the single intradermal comparative cervical tuberculin (SICCT) skin test. Our results demonstrated significantly better relative test sensitivity when the DIT was evaluated in a serial test scenario. Direct comparison of pre-and post-skin test blood samples revealed that the SICCT test induced significant boosting of the gamma interferon response in M. bovis-infected animals to both the ESAT-6 -CFP-10 and Rv3615c peptide cocktails that comprise the DIT, which persisted for the ESAT-6 -CFP-10 reagent for at least 14 days. Importantly, no similar boosting effects were observed in noninfected BCG vaccinates, suggesting that DIVA blood testing after a recent skin test would have minimal impact on test specificity.KEYWORDS blood test, bovine tuberculosis, DIVA, gamma interferon, Mycobacterium bovis, tuberculin skin test B ovine tuberculosis (TB) in cattle, caused predominantly by infection with Mycobacterium bovis, poses a significant economic animal health problem, where it has been estimated that globally the disease costs $3 billion U.S. annually (1). In Great Britain, bovine TB control measures are based on a test and cull program using the single intradermal comparative cervical tuberculin (SICCT) skin test as a primary diagnostic test, but also under certain circumstances the whole-blood interferon gamma (IFN-␥) release assay as an ancillary test to maximize detection of M. bovis-infected cattle. Despite this, the annual number of herd breakdowns remains high in the West of England and Wales, and thus new control strategies, including cattle vaccination, are under consideration. Studies with cattle have shown that M. bovis BCG vaccination significantly protected cattle following experimental infection with M. bovis, with some animals displaying no evidence of disease pathology in either the lungs or associated lymph nodes (2-4). However, these studies also highlight that BCG is not fully protective in all vaccinated animals, and as such, should BCG vaccination be implemented as

show abstract

Protection Induced by Simultaneous Subcutaneous and Endobronchial Vaccination with BCG/BCG and BCG/Adenovirus Expressing Antigen 85A against Mycobacterium bovis in Cattle

Cited by 32 publications

References 21 publications

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens

Tuberculin Skin Testing Boosts Interferon Gamma Responses to DIVA Reagents in Mycobacterium bovis-Infected Cattle

Contact Info

Product

Resources

About